Salute e Benessere

Ipsen and GENFIT Announce Positive Results from Phase III ELATIVE® trial of…

Trial met primary endpoint with a statistically significant higher percentage of patients achieving a clinically meaningful cholestasis response compared to placeboElafibranor was well tolerated with a safety profile consistent with previous studiesResults position elafibranor as a potentially important new treatment option, where there is still high unmet needIpsen intends to submit regulatory applications for elafibranor following discussions with the U.S. Food and Drug...
Nasdaq GlobeNewswire
30/06/2023

BioSenic provides financial update

INSIDE INFORMATIONLaunch of negotiation with main creditors Agreement with Global Tech Opportunities( GTO) to secure short term financing Mont-Saint-Guibert, Belgium, June 30, 2023, 7.00 am CEST – BIOSENIC(Euronext Brussels and Paris: BIOS), the innovative company addressing unmet medical needs in the areas of innate immunity, inflammation and organ/function repair, today provides a financial update.BioSenic has obtained an official appointment of Yves Brulard to reach...
Nasdaq GlobeNewswire
30/06/2023

Press release Biocartis Group NV: Disclosure of Outstanding Voting Securities

PRESS RELEASE - REGULATED INFORMATION30 June 2023, 7:00 CEST Disclosure of Outstanding Voting SecuritiesMechelen, Belgium,30 June 2023–Biocartis Group NV (the "Company" or "Biocartis"), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces that in the course of June 2023 4.50% convertible bonds due 2026 in a principal amount of EUR 495,900 were converted against the issuance of 445,977 shares of the Company.In view hereof, and in…
Nasdaq GlobeNewswire
30/06/2023

Ipsen and GENFIT Announce Positive Results from Phase III ELATIVE trial of…

Trial met primary endpoint with a statistically significant higher percentage of patients achieving a clinically meaningful cholestasis response compared to placebo Elafibranor was well tolerated with a safety profile consistent with previous studies Results position elafibranor as a potentially important new treatment option, where there is still high unmet needIpsen intends to submit regulatory applications for elafibranor following discussions with the U.S. Food and Drug...
Nasdaq GlobeNewswire
30/06/2023

ObsEva SA Announces that Shareholders Approved all Board Proposals at its 2023…

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss ExchangeGeneva, Switzerland – June 30 , 2023– ObsEva SA (SIX: OBSN), a biopharmaceutical company developing novel therapies for women's health, today announced that shareholders approved all Board proposals at its 2023 Annual General Meeting held on June 29, 2023. The approved items are as follows:Shareholders approved the Management Report, the Statutory Financial Statements and the Consolidated Financial Statements...
Nasdaq GlobeNewswire
30/06/2023

Bioheart (02185.HK) announces clinical result for Iberis-HTN at CIT 2023

Iberis®2nd is a catheter-based, procedure for the treatment of hypertension. Iberis®2nd has filed the registration application in China, received CE mark in EU in 2016 and has finished First in Human trial in Japan. Iberis® 2nd is currently the only RDN system globally with CE marking that can be used for both transradial approach (TRA) and transfemoral approach (TFA). TRA is preferred by interventionalists with fewer access site complications, shorter hospital stays and less overall procedural…
PR Newswire
30/06/2023

Liver Cancer Market to Proliferate Positively, Assesses DelveInsight | Key…

Key Takeaways from the Liver Cancer Market Report Key Takeaways from the Liver Cancer Market Report Discover which therapies are expected to grab the major liver cancer market share @Liver Cancer Market Report Liver Cancer Overview Liver cancer is a form of cancer that begins in the liver. It is the sixth most prevalent type of cancer diagnosed worldwide and the third leading cause of cancer death. The two most common histological subtypes of primary liver cancer are...
PR Newswire
29/06/2023

Endo Launches First Generic Version of Noxafil® (posaconazole) Injection

Posaconazole injection is indicated for prophylaxis of invasive Aspergillus and Candida infections in patients who are at high risk of developing these infections due to being severely immunocompromised, such as hematopoietic stem cell transplant (HSCT) recipients with graft-versus-host disease (GVHD) or those with hematologic malignancies with prolonged neutropenia (low white blood cell counts) from chemotherapy. Posaconazole injection is indicated for prophylaxis of invasiveAspergillusand...
PR Newswire
29/06/2023

Synergy Spine Solutions Announces First Patient Enrolled in the Synergy Disc®…

The Synergy Disc trial is a multi-center, prospective, non-randomized, historically controlled study that will be conducted on 200 patients at up to 25 sites. All patients in the study will receive the Synergy Disc. Patients will be evaluated preoperatively, at the time of surgery, immediately following surgery, at six weeks and three, six, 12 and 24 months after surgery. Follow-up will continue annually until the last patient reaches 24-month follow-up. The Synergy Disc trial is a...
PR Newswire
29/06/2023

dsm-firmenich announces results of extraordinary general meeting of shareholders

About dsm-firmenichAs innovators in nutrition, health, and beauty, dsm-firmenich reinvents, manufactures, and combines vital nutrients, flavors, and fragrances for the world's growing population to thrive. With our comprehensive range of solutions, with natural and renewable ingredients and renowned science and technology capabilities, we work to create what is essential for life, desirable for consumers, and more sustainable for the planet. dsm-firmenich is a Swiss-Dutch company, listed on the…
PR Newswire
29/06/2023

Kinarus Therapeutics Shareholders Approve All Board Proposals at the 2023 Annual…

Basel, Switzerland , 29June 2023 .Kinarus Therapeutics Holding AG (SIX: KNRS) (“Kinarus” or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respiratory, and ophthalmic diseases, announces that its shareholders have approved all proposals by the Board of Directors at the 2023 Annual General Meeting ("AGM"), held yesterday at the Radisson Blu Hotel Basel, Steinentorstrasse 25, 4051 Basel, Switzerland. In total…
Nasdaq GlobeNewswire
29/06/2023

NFL BIOSCIENCES: GB HOLDING TAKES A STAKE IN THE COMPANY'S CAPITAL UPON THE…

NFL BIOSCIENCES: GB HOLDING TAKES A STAKE IN THE COMPANY'S CAPITAL UPON THE EXERCISE OF SHARE SUBSCRIPTION WARRANTS AND PAYMENT OF 0.5M€, AND ALSO COMMITS TO ALOCK-UP NFL BIOSCIENCES (Euronext Growth Paris – FR0014003XT0 – ALNFL), a biopharmaceutical company developing botanical medicines for the treatment of drug dependencies and addictions, has been informed of the exercise of 100,000 share subscription warrants ("BSA") held by GB Holding, the holding company of Mr Gérard...
Nasdaq GlobeNewswire
29/06/2023

Near infrared imaging Market worth $1.9 billion | MarketsandMarkets

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=174869738 Download an Illustrative overview:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=174869738 Browse in-depth TOC on "Near infrared imaging Market"150 - Tables40 - Figures200 - Pages Near infrared imaging Market Scope: Product segment to register significant growth rate over the forecast period of 2023-2028 Based on the product, the global the...
PR Newswire
29/06/2023

Composite Resin Complete Removable Dentures Market to Grow at 4.8% CAGR and…

Global Composite Resin Complete Removable Dentures Market Forecast Analysis: Global Composite Resin Complete Removable Dentures Market Forecast Analysis: As per the report published by Research Dive, theglobal composite resin complete removable dentures market is expected to register a revenue of$185.5 millionby 2031 at a CAGR of 4.8% during the forecast period 2022-2031. Segments of the Composite Resin Complete Removable Dentures Market The report has divided the market...
PR Newswire
29/06/2023

Alkermes Shareholders Re-Elect All Seven Company Director Nominees at 2023…

Nancy J. Wysenski, Lead Independent Director of Alkermes' Board of Directors, said, "We are pleased that all seven Company nominees were re-elected to the Board and appreciate the active engagement with our shareholders as well as their feedback and support. We believe this outcome is a reflection of our strong performance and robust corporate governance practices. Looking ahead, we remain focused on executing on our strategic priorities for the benefit of all shareholders, including our…
PR Newswire
29/06/2023

PocDoc partners with NHS Targeted Lung Health Programme in North East…

Seventy percent of those attending for TLHC scans will have coronary artery calcium (CAC) – a new marker of heightened risk of a heart attack or stroke which is identified during the scan. Discovering these higher risk patients who have evidence of early disease, but are not already taking a statin, is an optimal way to maximise the health outcomes of the TLHC program. This could potentially reduce both cancer and cardiovascular deaths through a single test. Seventy percent of those attending...
PR Newswire
29/06/2023

Dental Cartridge Syringe Market to Reach $0.19 Billion, Globally, by 2032 at…

Download Sample Copy- https://www.alliedmarketresearch.com/request-sample/50977 Download Sample Copy-https://www.alliedmarketresearch.com/request-sample/50977 Prime determinants of growth Rise in the incidences of dental and oral diseases such as tooth decay and gum disease, increase in geriatric population suffering from oral diseases, and high adoption of non-disposable cartridge syringes due to higher availability and various benefits associated with non-disposable cartridge...
PR Newswire
29/06/2023

Curia wins 2023 Frost & Sullivan Customer Value Leadership Award

Curia recognized for providing a best-in-class customer experience in the CRDMO industry through its innovative approach and growth strategy “We are very honored to be recognized with this award, which underlines the hard work and dedication of all of our employees to delivering quality and reliability when serving our customers,” said Philip Macnabb, CEO, Curia. “We remain steadfast in our noble purpose of improving patients' lives, a mission that begins with our commitment to creating...
Nasdaq GlobeNewswire
29/06/2023

Intravacc publishes 2022 annual report

Intravacc is also pleased to announce the newly appointed Vice President Business Development & Marketing (VP BD&M) Mrs. Frieda Gerdes, PhD. Frieda, is a seasoned professional with over 25 years of experience in the healthcare industry. After receiving her PhD in cell biology from the University of Kiel in Germany, she began her career in 1996 in sales and has since held various leading positions in marketing and business development at companies such as ThermoFisher Scientific, Agendia…
PR Newswire
29/06/2023

Cresilon Receives First FDA Clearance For Human Use of Hemostatic Gel Technology

CHG™ utilizes Cresilon's proprietary hemostatic gel technology that rapidly controls bleeding when applied to a wound ‒ without the need for manual pressure. In addition to its versatility, the plant-based gel is easy-to-use and works instantaneously to both stop and control bleeding at the point of care CHG™ utilizes Cresilon's proprietary hemostatic gel technology that rapidly controls bleeding when applied to a wound ‒ without the need for manual pressure. In addition to its versatility…
PR Newswire
29/06/2023

Endo Announces Approval of XCOPRI™ (cenobamate tablets) in Canada

Paladin Labs is working collaboratively with the Canadian Agency for Drugs and Technologies in Health (CADTH) and the Institut national d'excellence en santé et en services sociaux (INESSS) to ensure appropriate patients have access to XCOPRI™. Paladin Labs is working collaboratively with the Canadian Agency for Drugs and Technologies in Health (CADTH) and the Institut national d'excellence en santé et en services sociaux (INESSS) to ensure appropriate patients have access to XCOPRI ™...
PR Newswire
29/06/2023

BioNTech and OncoC4 Initiate Pivotal Phase 3 Trial of BNT316/ONC-392 Program in…

Initiation of pivotal Phase 3 trial in non-small cell lung cancer (NSCLC) marks the first landmark in BioNTech's and OncoC4's strategic collaboration initiated in March 2023 with the aim to evaluate BNT316/ONC-392 in various solid tumor indications The randomized Phase 3 trial is expected to enroll approximately 600 patients with metastatic, immunotherapy-resistant NSCLC at clinical trial sites initially in the United States, followed by Europe and other countries and regionsThe...
Nasdaq GlobeNewswire
29/06/2023

Domain Therapeutics announces nomination of best-in-class CCR8 antibody…

Domain Therapeutics announces nomination of best-in-class CCR8 antibody candidate, DT-7012, further strengtheningits unique portfolio of GPCR-targeting immunotherapies DT-7012 nominated based on its unique ability , as a monotherapy, to cure cancer in preclinical studiesPhase Istudy with DT-7012 expected to start by mid-2025 Follows recent candidate nomination of a novel Negative Allosteric Modulators (NAM) of protease-activated...
Nasdaq GlobeNewswire
29/06/2023

DelSiTech announces positive topline clinical data from phase 1 trial with its…

Kai Kaarniranta, the Principal Investigator of the study, Professor of Ophthalmology and Chief Physician of Department of Ophthalmology in Kuopio University Hospital, in Kuopio, Finland commented: "The human eye is an extremely sensitive organ and as such, it is common for eye drops to cause at least mild discomfort upon dosing. Based on a variety of objective ophthalmic test methods for both the front and back of the eye, DelSiTech's eye drop technology has been proven in this study to be…
PR Newswire
29/06/2023
Altri  Comunicati